Grupo 2
Oncología Médica Traslacional y Terapia Individualizada del Cáncer
Publicaciones (831)
-
Perez-Fidalgo, JA; Ortega, E; Ponce, J; Redondo, A; Sevilla, I; Valverde, C; Verdum, JI; de Alava, E; Lopez, MG; Marquina, G; Sebio, A.
Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
Therapeutic Advances in Medical Oncology. 2023; 15: Nº de citas: 5 [doi:10.1177/17588359231157645]
-
Jimenez-Fonseca, P; Foy, V; Raby, S; Carmona-Bayonas, A; Macia-Rivas, L; Arrazubi, V; Lavin, DC; Gil, RHS; Custodio, A; Cano, JM; Montes, AF; Mirallas, O; Declara, IM; Tocino, RV; Visa, L; Limon, ML; Pimentel, P; Lago, NM; Sauri, T; Richard, MM; Mangas, M; Raga, MG; Calvo, A; Reguera, P; Granja, M; Carnicero, AM; Perez, CH; Cerda, P; Gonzalez, LG; Navalon, FG; Barcia, VP; Abad, D; Martin, MR; Weaver, J; Mansoor, W; Gallego, J.
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology. 2023; 15: Nº de citas: 2 [doi:10.1177/17588359231157641]
-
Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B.
Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Revista Espanola de Patologia. 2023; 56(1): 32-44 [doi:10.1016/j.patol.2022.06.004]
-
Yu EY; Piulats JM; Gravis G; Fong PCC; Todenhöfer T; Laguerre B; Arranz JA; Oudard S; Massard C; Heinzelbecker J; Nordquist LT; Carles J; Kolinsky MP; Augustin M; Gurney H; Tafreshi A; Li XT; Qiu P; Poehlein CH; Schloss C; de Bono JS.
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
EUROPEAN UROLOGY. 2023; 83(1): 15-26 Nº de citas: 47 [doi:10.1016/j.eururo.2022.08.005]
-
Johnston SRD; Toi, M; O'Shaughnessy, J; Rastogi, P; Campone, M; Neven, P; Huang, CS; Huober, J; Jaliffe, GG; Cicin, I; Tolaney, SM; Goetz, MP; Rugo, HS; Senkus, E; Testa, L; Del Mastro, L; Shimizu, C; Wei, R; Shahir, A; Munoz, M; San Antonio, B; André V; Harbeck, N; Martin, M.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
LANCET ONCOLOGY. 2023; 24(1): 77-90 Nº de citas: 363 [doi:10.1016/S1470-2045(22)00694-5]
-
Arance, A; De La Cruz-Merino, L; Petrella, TM; Jamal, R; Ny, L; Carneiro, A; Berrocal, A; Marquez-Rodas, I; Spreafico, A; Atkinson, V; Costa Svedman F; Mant, A; Khattak, MA; Mihalcioiu, C; Jang, S; Cowey, CL; Smith, AD; Hawk, N; Chen, K; Diede, SJ; Krepler, C; Long, GV.
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(1): 75-85 Nº de citas: 81 [doi:10.1200/JCO.22.00221]
-
Munoz, A; Gallardo, E; Agnelli, G; Crespo, C; Forghani, M; Arumi, D; de Cabo, SF; Soto, J.
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain
Journal of Medical Economics. 2022; 25(1): 840-847 Nº de citas: 9 [doi:10.1080/13696998.2022.2087998]
-
Escobar, Y; Margarit, C; Perez-Hernandez, C; Quintanar, T; Virizuela, JA.
Good practice recommendations to better coordinate the management of oncological pain: a Delphi survey
Scientific Reports. 2022; 12(1): 22459-22459 Nº de citas: 4 [doi:10.1038/s41598-022-26753-3]
-
Lemos, R; Areias-Marques, S; Ferreira, P; O'Brien, P; Beltran-Jaunsaras, ME; Ribeiro, G; Martin, M; Del Monte-Millan, M; Lopez-Tarruella, S; Massarrah, T; Luis-Ferreira, F; Frau, G; Venios, S; McManus, G; Oliveira-Maia, AJ.
A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol
BMC Psychiatry. 2022; 22(1): Nº de citas: 4 [doi:10.1186/s12888-022-04446-5]
-
Valladares-Ayerbes, M; Garcia-Alfonso, P; Luengo, JM; Caceres, PPP; Trujillo, OAC; Vidal-Tocino, R; Llanos, M; Ayala, BL; Miron, MLL; Salud, A; Nogueras, LC; Garcia-Carbonero, R; Safont, MJ; Ferrer, EF; Aparicio, J; Conesa, MAV; Guillen-Ponce, C; Garcia-Teijido, P; Magan, MBM; Busquier, I; Salgado, M; Vila, AL; PERSEIDA Investigators.
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Cancers. 2022; 14(24): Nº de citas: 5 [doi:10.3390/cancers14246075]
-
Argiles, G; Mulet, N; Valladares-Ayerbes, M; Vieitez, JM; Gravalos, C; Garcia-Alfonso, P; Santos, C; Tobena, M; Garcia-Paredes, B; Benavides, M; Cano, MT; Loupakis, F; Rodriguez-Garrote, M; Rivera, F; Goldberg, RM; Cremolini, C; Bennouna, J; Ciardiello, F; Tabernero, JM; Aranda, E; Tabernero, J.
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
EUROPEAN JOURNAL OF CANCER. 2022; 177: 154-163 Nº de citas: 6 [doi:10.1016/j.ejca.2022.09.037]
-
Schettini, F; Venturini, S; Giuliano, M; Lambertini, M; Pinato, DJ; Onesti, CE; De Placido, P; Harbeck, N; Lueftner, D; Denys, H; Van Dam, P; Arpino, G; Zaman, K; Mustacchi, G; Gligorov, J; Awada, A; Campone, M; Wildiers, H; Gennari, A; Tjan-Heijnen, V; Bartsch, R; Cortes, J; Paris, I; Martin, M; De Placido, S; Del Mastro, L; Jerusalem, G; Curigliano, G; Prat, A; Generali, D.
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
CANCER TREATMENT REVIEWS. 2022; 111: Nº de citas: 22 [doi:10.1016/j.ctrv.2022.102468]
-
Bofill, JS; Anton, FM; Sanchez, CAR; Calvo, EG; Melia, CH; Gil, EMC; Vidal, M; Jimenez-Rodriguez, B; Merino, LD; Janez, NM; Vazquez, RV; Salas, RD; Torres, AA; Lopez, IMA; Gregori, JG; Garcia, VQ; Rubio, EV; De la Haba-Rodriguez, J; Gonzalez-Santiago, S; Fernandez, ND; Molins, AB; De Ibarguen, BCS; Mingorance, JID; Ezquerra, MB; De Casa, S; Gimeno, A; Martin, M.
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
BREAST. 2022; 66: 77-84 Nº de citas: 5 [doi:10.1016/j.breast.2022.09.006]
-
Taboada AGM; Lominchar PL; Martínez MF; García-Alfonso P; Martin AM; Asencio JM.
Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline".
Annals Of Hepato-Biliary-Pancreatic Surgery. 2022; 26(4): 363-374 Nº de citas: 1 [doi:10.14701/ahbps.22-023]
-
Villanueva-Bueno C; Collado-Borrell R; Escudero-Vilaplana V; Revuelta-Herrero JL; Marzal-Alfaro MB; González-Haba E; Arranz-Arija JÁ; Osorio S; Herranz-Alonso A; Sanjurjo-Saez M.
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital.
Frontiers in Public Health. 2022; 10: 978783-978783 Nº de citas: 3 [doi:10.3389/fpubh.2022.978783]
-
García Adrián S; Gonzalez, AR; De Castro, EM; Olmos, VP; Moran, LO; del Prado, PM; Fernandez, MS; Burón JDC; Escobar, IG; Galan, JM; Pérez AIF; Neria, F; Lavin, DC; Hernández BLSV; Jimenez-Fonseca, P; Muñoz Martín AJ.
Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis
EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2022; 105: 30-37 Nº de citas: 10 [doi:10.1016/j.ejim.2022.07.020]
-
Quinaglia T; Gongora C; Awadalla M; Hassan MZO; Zafar A; Drobni ZD; Mahmood SS; Zhang L; Coelho-Filho OR; Suero-Abreu GA; Rizvi MA; Sahni G; Mandawat A; Zatarain-Nicolás E; Mahmoudi M; Sullivan R; Ganatra S; Heinzerling LM; Thuny F; Ederhy S; Gilman HK; Sama S; Nikolaidou S; Mansilla AG; Calles A; Cabral M; Fernández-Avilés F; Gavira JJ; González NS; García de Yébenes Castro M; Barac A; Afilalo J; Zlotoff DA; Zubiri L; Reynolds KL; Devereux R; Hung J; Picard MH; Yang EH; Gupta D; Michel C; Lyon AR; Chen CL; Nohria A; Fradley MG; Thavendiranathan P; Neilan TG.
Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis
JACC-Cardiovascular Imaging. 2022; 15(11): 1883-1896 Nº de citas: 23 [doi:10.1016/j.jcmg.2022.06.014]
-
de la Rosa, CA; Castellanos, PC; Lazaro-Quintela, M; Domine, M; Estevez, SV; Lopez-Vivanco, G; Perez, JLF; Romero, JLA; Delgado, LF; Giron, CG; Tain, PD; Alvarez, RA; Sanchis, PM; Canton, IF; Abos, IM; Aguillo, MM; Gutierrez, LGA; Granados, ALO; Cabellos, RA; Sebastian, AG; Sifuentes, LFG; Reguart, N.
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
LUNG CANCER. 2022; 173: 83-93 Nº de citas: 7 [doi:10.1016/j.lungcan.2022.09.010]